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Inflammatory bowel diseases (IBD), including Crohn’s disease 
and ulcerative colitis, are idiopathic chronic intestinal inflam-
matory diseases, characterized by recurrent episodes of relapse 
and remission of disease. The introduction of anti-tumor necro-
sis factor (anti-TNF) agents has greatly improved the treatment 
outcomes for IBDs, enabling higher rates of clinical and endo-
scopic remission in patients who are refractory to conventional 
therapies such as corticosteroids and thiopurines.1,2 Despite 
the proven therapeutic efficacy of anti-TNF agents, treatment 
failures to those sometimes occur in the form of primary nonre-
sponse or secondary loss of response (LOR). 
About 10% to 20% of IBD patients have been reported to be 
unresponsive to induction treatment with anti-TNF agents.3 The 
mechanism of this primary nonresponse is unclear. Meanwhile, 
of the patients who initially respond to anti-TNF treatment, a 
significant proportion loses response over time with annual risk 
of 13% to 24%.4 Several distinct mechanisms for secondary 
LOR have been suggested, including the formation of antidrug 
antibodies (ADA), nonimmune drug clearance, relentless TNF-
mediated flare consuming the anti-TNF agent, shift of disease 
pathway away from TNF, as well as non-IBD related mecha-
nisms such as irritable bowel syndrome, infection, cancer, and 
so forth.5 To prevent LOR to anti-TNF treatment, scheduled 
treatment rather than episodic therapy and combination therapy 
with immunomodulators than anti-TNF monotherapy are rec-
ommended.6
In patients presenting with LOR to anti-TNF agents, after ex-
cluding non-IBD, noninflammatory causes, several therapeutic 
options such as dose intensification, switching to another anti-
TNF agents, and switching to another biologics with different 
mechanism of action would be considered. In these circum-
stances, pharmacokinetic measurements of anti-TNF trough 
levels (TL) and ADA could be useful to elucidate mechanisms of 
LOR and guide selection of most appropriate therapeutic strat-
egy.3
Several studies have demonstrated clinical importance of 
therapeutic drug monitoring (TDM) of anti-TNF agents by de-
termining drug levels and ADA in terms of a tailored approach 
to IBD patients. Higher anti-TNF TLs have been associated with 
better clinical outcomes and endoscopic improvement, while 
undetectable anti-TNF TLs were related to loss of clinical re-
sponse and higher risk for surgery. On the contrary, immuno-
genicity (formation of ADA) has been known to accelerate anti-
TNF clearance and increase the risk of infusion reaction to anti-
TNF agents, although the exact clinical impact of ADA on anti-
TNF efficacy is still controversial.7 In Western countries, clinical 
decision algorithms with TDM based on drug levels and ADA 
for the management of IBD patients with LOR, to optimize the 
efficacy of anti-TNF and then to reduce health-related cost, has 
been proposed and widely performed in clinical practice.8 In 
addition, some researchers have suggested that proactive TDM 
will be promising even for IBD patients in clinical remission, to 
maintain optimal anti-TNF concentrations and then to reduce 
costs and risk for adverse events.7
However, most of these studies have been performed in West-
ern countries. To date, there has been no data regarding TDM 
and its impact on clinical outcomes and medical costs in Korean 
IBD patients with secondary LOR. And, measurements of drug 
levels and ADA are not yet available in Korea.
In this issue of Gut and Liver, Choi et al.9 investigated the 
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clinical usefulness of infliximab (IFX) TLs and ADA in 39 pe-
diatric IBD patients in a retrospective manner and proposed a 
tailored therapeutic strategy for IFX therapy based on IFX TLs 
and ADA status in patients with LOR. They compared serum 
IFX TLs and ADA between 16 patients with clinical remission 
and 23 patients with a poor response to IFX treatment and re-
measured the IFX TLs and ADA after IFX dose intensification 
in 21 patients with LOR. The authors showed that the IFX TLs 
were significantly higher in patients with clinical remission than 
those with a poor response (median, 3.99 μg/mL vs 0.88 μg/mL; 
p=0.002) and the ADA was detectable in only patients with LOR 
(7/23, 30.4%). In addition, after IFX dose intensification in pa-
tients with LOR, the IFX TLs were increased in 17 patients with 
improved response, while four patients with no response have 
no detectable IFX but detectable ADA. This study, firstly evalu-
ated the efficacy of anti-TNF TLs and ADA in Korean IBD pa-
tients, provide a valuable clinical insight into the TDM of anti-
TNF agents for IBD patients with secondary LOR in Korea. 
However, as the authors described, this study performed 
retrospectively with a small sample size and did not evaluate 
clinical outcomes and response to dose intensification of IFX in 
the long-term. To validate the results of this study, especially 
in adult patients, a prospective multicenter long-term clini-
cal trial with a larger sample size in Korean IBD patients with 
anti-TNF treatments should be conducted. One of these would 
undoubtedly be the OACIS study from KASID (Korean associa-
tion for the study of intestinal diseases), a prospective, open-
label, multicenter trial for the occurrence of ADA and change 
of drug level after anti-TNF therapy and their impact on clinical 
outcomes in moderate to severe IBD.
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